{
    "nct_id": "NCT03563716",
    "official_title": "A Phase II, Randomized, Blinded, Placebo-Controlled Study of Tiragolumab, An Anti-TIGIT Antibody, In Combination With Atezolizumab In Chemotherapy-NaÃ¯ve Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer",
    "inclusion_criteria": "* ECOG Performance Status of 0 or 1\n* Histologically or cytologically documented locally advanced unresectable NSCLC, recurrent, or metastatic NSCLC of either squamous or non-squamous histology\n* No prior systemic treatment for locally advanced unresectable or metastatic NSCLC\n* Tumor PD-L1 expression\n* Measurable disease, as defined by RECIST v1.1\n* Life expectancy >=12 weeks\n* Adequate hematologic and end-organ function\n* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods, and agreement to refrain from donating eggs\n* For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "Cancer-Specific Exclusions:\n\n* Patients with NSCLC known to have a sensitizing mutation in the EGFR gene or an ALK fusion oncogene\n* Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases\n* Spinal cord compression not definitively treated with surgery and/or radiation, and/or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for >=2 weeks prior to screening\n* History of leptomeningeal disease\n* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures\n* Uncontrolled tumor-related pain\n* Uncontrolled hypercalcemia or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy or denosumab\n* Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death and/or treated with expected curative outcome\n\nGeneral Medical Exclusions:\n\n* Pregnant and lactating women\n* Significant cardiovascular disease\n* Severe infections within 4 weeks prior to randomization\n* Major surgical procedure other than for diagnosis within 4 weeks prior to randomization\n\nTreatment-Specific Exclusions:\n\n* History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins; known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation\n* History of autoimmune disease\n* Prior allogeneic bone marrow transplantation or solid organ transplantation\n* History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan\n* Positive test for human immunodeficiency virus (HIV) and/or active hepatitis B or hepatitis C or active tuberculosis\n* Administration of a live, attenuated vaccine within 4 weeks prior to randomization",
    "miscellaneous_criteria": ""
}